Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION)

NCT03511664 PHASE3 COMPLETED Results posted

The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.

Details

Lead sponsor	Endocyte
Phase	PHASE3
Status	COMPLETED
Enrolment	861
Start date	Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Prostate Cancer

Interventions

• 177Lu-PSMA-617
• Best supportive/best standard of care

Countries

Denmark, France, Netherlands, Belgium, Sweden, United Kingdom, Germany, Canada, Puerto Rico, United States